Caribou Biosciences (CRBU) Receivables (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Receivables of $1.7 million for Q1 2026, down 13.46% year-over-year from $1.9 million in Q1 2025, and up 1053.1% quarter-over-quarter from $145000.0 in Q4 2025.
Caribou Biosciences (CRBU) Receivables (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Receivables for 7 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 13.46% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 13.46% YoY), while the FY2025 annual figure was $2.0 million, down 5.73% from the prior year.
- Receivables grew to $1.7 million in Q1 2026 per CRBU's latest filing, from $145000.0 in the prior quarter.
- Across five years, Receivables topped out at $4.5 million in Q1 2022 and bottomed at -$283000.0 in Q4 2022.
- Historically, Receivables has averaged $2.0 million across 5 years, with a median of $2.0 million in 2025.
- Annual changes were most pronounced in 2022 — Receivables plunged 122.11% — and 2024, when it jumped 360.67%.
- Caribou Biosciences' Receivables stood at -$283000.0 in 2022, then jumped by 131.45% to $89000.0 in 2023, then surged by 360.67% to $410000.0 in 2024, then tumbled by 64.63% to $145000.0 in 2025, then soared by 1053.1% to $1.7 million in 2026.
- Business Quant data shows CRBU's Receivables at $1.7 million in Q1 2026, $145000.0 in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Caribou Biosciences | 163.09 Mn | 50.78 Mn | - | 1.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.34 Mn |
| Mar 31, 2026 | 1.67 Mn |
| Dec 31, 2025 | 145,000.00 |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 1.93 Mn |
| Dec 31, 2024 | 410,000.00 |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | 2.64 Mn |
| Dec 31, 2023 | 89,000.00 |
| Sep 30, 2023 | 3.48 Mn |
| Jun 30, 2023 | 2.26 Mn |
| Mar 31, 2023 | 3.20 Mn |
| Dec 31, 2022 | -283,000.00 |
| Sep 30, 2022 | 3.10 Mn |
| Jun 30, 2022 | 3.62 Mn |
| Mar 31, 2022 | 4.54 Mn |
| Dec 31, 2021 | 1.28 Mn |
| Sep 30, 2021 | 5.93 Mn |